Flinn IW, et al. - In this open-label, global phase II trial, researchers assessed the safety and efficacy of duvelisib monotherapy (a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ) in indolent non-Hodgkin lymphoma (iNHL) refractory to rituximab and either chemotherapy or radioimmunotherapy. Participants were patients with measurable iNHL (follicular lymphoma [FL], small lymphocytic lymphoma [SLL], or marginal zone B-cell lymphoma) double refractory to rituximab (monotherapy or in combination) and to either chemotherapy or radioimmunotherapy. Until progression, unacceptable toxicity, or death, all received duvelisib 25 mg orally twice daily in 28-day cycles. A total of 129 patients (median age, 65 years; median of three prior lines of therapy) were included. The estimated overall response rate (ORR) was 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). Findings were consistent with previous observations and revealed clinically meaningful activity and a manageable safety profile of oral duvelisib monotherapy in heavily pretreated, double-refractory iNHL in the DYNAMO study. Duvelisib could be a novel oral treatment option for this patient population.